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fatty acids and fatty acid derivatives such as 15-deoxy-⌬ 12,14 -prostaglandin J 2 (3) . After ligand activation, PPAR␥ changes its conformational structure, which facilitates the release of corepressors and subsequent binding of a distinct set of nuclear coactivators, resulting in the regulation of gene transcription (2, 6) .
PPAR␥ activation through binding of the synthetic TZDs results in a marked improvement in type 2 diabetic patients of insulin and glucose parameters resulting from an improvement of whole body insulin sensitivity (4, 21, 24, 28) . The mechanism of PPAR␥-mediated insulin sensitization by TZDs is still unclear. Despite the importance of skeletal muscle in insulininduced glucose disposal, adipose tissue seems to be the major mediator of PPAR␥ action on insulin sensitivity. PPAR␥ has the highest expression levels in adipose tissue compared with other metabolic organs, such as skeletal muscle, liver, and pancreas (36) . PPAR␥ is the master regulator of adipogenesis, thereby stimulating the production of small insulin-sensitive adipocytes (15, 35) . The induction of adipogenesis associated with the capability for fatty acid trapping has been shown to be an important contributor to the maintainance of systemic insulin sensitivity. (33) In addition, PPAR␥ activation in mature adipoyctes induces a number of genes involved in the insulinsignaling cascade, thereby improving insulin sensitivity (20, 30, 34) . However, there is still debate about the role of other metabolic tissues in mediating PPAR␥-function in glucose and insulin homeostasis. Recently, the function of PPAR␥ in adipose tissue and skeletal muscle has been intensively characterized by using targeted deletion of PPAR␥ in those tissues.
PPAR␥ FUNCTION: LESSONS FROM TISSUE-SPECIFIC KNOCKOUT MICE

PPAR␥ Deficiency in Fat
A study by He et al. (8) utilized the Cre-recombinase-loxP system to generate mice with PPAR␥ deficiency only in fat. As a result of the LoxP site location on either side of exons 1 and 2 of the PPAR␥ gene, a complete loss of the PPAR␥1 isoform and translation of a nonfunctional PPAR␥2 isoform were achieved after Cre-mediated deletion. Placement of Cre cDNA under the control of the adipose-specific fatty acid-binding protein (aP2) promoter resulted in fat-specific deletion of PPAR␥. aP2 is a downstream target of PPAR␥ during adipocyte differentiation (13) . Usage of the aP2 promoter, therefore, deletes PPAR␥ after normal differentiation in adipocytes. This strategy allows one to study the role of PPAR␥-mediated functions in mature adipocytes, but not during the early processes of adipogenesis.
Mice carrying the deletion of PPAR␥ in mature adipocytes showed a marked decrease of brown and white adipose mass, with Ͼ80% loss of white adipocytes (8) . Adipocyte loss was compensated for by a hypertrophic response of the remaining adipocytes and an inflammatory reaction in adipose tissue (8) . Metabolic measurements in adipose PPAR␥-deficient mice demonstrated marked hyperlipidemia with elevated free fatty acid (FFA) and trigylceride levels, associated with a significant decrease in plasma adipocytokines (leptin, adiponectin). Despite these metabolic changes, systemic insulin sensitivity was maintained with no changes in fasting glucose and insulin levels, as well as no changes in glucose and insulin tolerance tests. However, adipocyte PPAR␥ was required to maintain insulin sensitivity in mice fed a high-fat diet. Insulin responsiveness of different metabolic organs, including adipose tissue, skeletal muscle, and liver, was tested in clamp studies under normal chow diet. These experiments revealed the presence of adipose tissue and hepatic insulin resistance, whereas muscle insulin sensitivity was maintained. Liver insulin resistance was a result of hepatic lipid accummulation (8) .
TZD treatment in patients results in prominent improvement of whole body insulin sensitivity; however, the targeted metabolic tissue responsible for these effects is still unknown (4, 21, 28) . To further clarify the insulin-sensitizing mechanism of TZDs, adipose PPAR␥-deficient and control mice were treated with rosiglitazone (8) . TZD treatment lowered FFA levels in control mice, which was not observed in adipocyte PPAR␥-deficient mice, indicating that TZD-mediated regulation of plasma FFAs is dependent on PPAR␥ function in intact adipose tissue. Hepatic insulin resistance was not affected by TZD treatment.
Previous studies in fatless and lipodystrophic animal models revealed the development of systemic insulin resistance and diabetes. Surgical reimplantation of adipose tissue reversed the diabetic state in those animals, underscoring the importance of adipose tissue in maintaining insulin and glucose homeostasis (5, 22) . Lack of PPAR␥ in mature adipocytes did impair insulin sensitivity under high-fat diet conditions, a nutritional environment prevalent in industrialized countries and rising in developing nations (8) . Against the background of this epidemic in overnutrition, the importance of adipose PPAR␥ in maintaining intact systemic insulin sensitivity is evident from the study by He et al. (8) . Impaired PPAR␥ function in fat resulted in hepatic insulin resistance. Unfortunately, muscle insulin sensitivity has not yet been evaluated in adipose PPAR␥-deficient mice fed a high-fat diet. A further increase in FFA accumulation in skeletal muscle in response to a high-fat diet should also contribute to muscular insulin resistance. PPAR␥ deficiency in adipocytes also demonstrated that adipose tissue is a major mediator of TZD effects to decrease circulating FFAs by inhibiting lipolysis in fat. This mechanism is likely a major contributor to TZD insulin-sensitizing activity (17, 26, 27) . Although the elegant work of He et al. provided important insight concerning the role of PPAR␥ function in mature adipocytes, it did not examine the role of this nuclear receptor in producing new insulin-sensitive, small adipocytes.
What is the role of PPAR␥ during the initiation of adipoycte differentiation? Koutnikova et al. (14) utilized a complex approach by introducing a genomic modification near exon B (introduction of a neomycin cassette 500 bp downstream) of the PPAR␥2 isoform. The sole presence of the selection marker in proximity to exon B resulted in an almost complete loss of PPAR␥2 in brown and white adipose tissue, as well as in liver and muscle. PPAR␥1 is a downstream target of PPAR␥2 during differentiation of white adipocytes, so it was not surprising that the PPAR␥1 isoform was also undetectable in white adipose tissue (29, 32) . In contrast, in brown adipose tissue the loss of PPAR␥2 was compensated for by an increase in PPAR␥1 expression. PPAR␥1 mRNA expression level in muscle and liver remained unchanged. Because PPAR␥2 is expressed predominantly in white adipose tissue, this model serves as an adipose-specific PPAR␥ knockdown.
One-week-old animals homozygous for the mutation had no white adipose tissue associated with a massive hepatomegaly due to steatosis and accummulation of lipids in heart, skeletal muscle, and kidneys (14) . Serum FFA and triglyceride levels were dramatically elevated in young lypodystrophic animals. Adult mice showed significantly higher glucose levels during a glucose tolerance test, as well as increased glucose and insulin levels during regular feeding, indicating a state of insulin resistance in these animals. Serum FFA and triglyceride levels were decreased during adulthood in PPAR␥ adipose tissue knockdown mice despite their remaining lypodystrophic. Decreased plasma triglyceride and FFA levels likely resulted from a compensatory increase in FFA catabolism in skeletal muscle, since multiple genes involved in FFA oxidation were induced in muscle tissue of mutant animals. ␤-Oxidation genes in the liver, however, remained unchanged, and genes for hepatic gluconeogenesis were induced. These together led the authors to the conclusion that, in the absence of white adipose tissue, PPAR␥ in the liver contributes to impaired glucose tolerance, whereas the muscle might be a major compensatory organ for lipid metabolism (14) .
Zhang et al. (38) selectively disrupted the PPAR␥2 isoform in mice by replacing the initiation codon and the partial exon B with a red fluorescence protein-coding sequence and the neomycin gene cassette. PPAR␥2 deletion resulted in a marked reduction of white adipose tissue mass, whereas brown adipose tissue mass was normal (38) . PPAR␥2-deficient mice had impaired insulin sensitivity, as measured in an insulin tolerance test. However, insulin sensitivity was impaired only in male mice, not in female animals, suggesting a sex-specific regulation of PPAR␥2-dependent insulin and glucose metabolism (38) . Surprisingly, in the study by Zhang et al., lypodystrophy in PPAR␥2-deficient mice did not result in lipid accumulation in nonadipose tissue (e.g., liver), and circulating triglyceride and cholesterol levels were equal among the groups. In addition, food intake and body weight were similar between wildtype and PPAR␥2-deficient mice, and one has to ask where incorporated substrates (carbohydrates, fatty acids, etc.) are stored in lypodystrophic PPAR␥2-deficient mice. Treatment of PPAR␥2-deficient mice with the PPAR␥ ligand rosiglitazone still led to a normalization of systemic insulin resistance, suggesting that PPAR␥2 is not essential for TZD-mediated insulin sensitization in this model (38) .
What Have We Learned from PPAR␥ Deficiency in Fat?
The three studies discussed demonstrated that PPAR␥ is essential for the development and normal function of white adipose tissue (8, 14, 38) . They have elegantly shown that PPAR␥ is required to keep up intact insulin sensitivity during caloric intake, even gaining importance during intake of highfat diets. Certain mechanisms of the maintainance of insulin sensitivity through adipose PPAR␥ have been identified. By maintaining the intact function of white adipose tissue, PPAR␥ protects the liver against lipid overload, thereby ensuring intact hepatic insulin sensitivity. Adipose PPAR␥ guarantees a balanced and adequate regulation of secretion from adipose tissue of adipocytokines such as adiponectin and leptin, which are major contributors to a regular insulin response (7, 10, 19, 37) . The role of skeletal muscle during these processes still remains unclear. Previous studies have shown that lypodystrophic or fatless animals develop severe insulin resistance and diabetes, mainly as a result of impaired muscular glucose diposal due to lipid accummulation and subsequent lipotoxicity (22, 27) . However, He et al. (8) obeserved an intact insulin sensitivity in skeletal muscle of adipose PPAR␥-deficient mice despite a marked accummulation of lipids. They hypothesized that a certain threshold of lipid accumulation must be reached in skeletal muscle to induce lipotoxic insulin resistance in skeletal muscle. This threshold is likely to be attained during intake of high-fat diets. Unfortunately, the authors did not perform these experiments in their study. In addition, Koutnikova et al. (14) demonstrated that the loss of PPAR␥ induced the expression of genes involved in muscular ␤-oxidation, thereby providing a compensatory enhanced FFA catabolism in skeletal muscle, contributing to the clearance of FFAs (23) . Compensatory FFA catabolism, however, did not affect the insulin-resistant state in mutant animals (14) . In addition, despite a decrease in serum FFA levels in adult animals, FFA serum levels were still elevated during caloric intake (14) . Finally, increased muscular FFA oxidation could not prevent lipid accummulation in skeletal muscle of mutant animals, assuming the continued presence of lipotoxic impairment of muscular glucose metabolism (14) . Further experiments are required to characterize the role of compensatory muscular FFA oxidation in the regulation of whole body lipid and glucose metabolism after adipocytic PPAR␥ loss.
In summary, two major mechanisms of adipose PPAR␥-mediated preservation of systemic insulin sensitivity have been identified: 1) protection of nonadipose tissue against excessive lipid overload and maintainance of regular organ function (liver, skeletal muscle), and 2) balanced and adequate regulation of adipocytokine secretion (adiponectin, leptin).
Although PPAR␥ expressed in liver and skeletal muscle contributes importantly to glucose and lipid metabolism, these early and elegant studies using tissue-specific PPAR␥ knockout mouse models pinpoint adipose tissue as the major target of TZD-mediated improvement of hyperlipidemia and insulinsensitization (8, 14) .
PPAR␥ Deficiency in Skeletal Muscle
To further study the role of skeletal muscle in PPAR␥-mediated regulation of insulin and glucose metabolism, Hevener et al. (9) , as well as Norris et al. (25) , produced mice with a skeletal muscle-specific deletion of PPAR␥. LoxP sites flanked exon 1 and/or 2 of the PPAR␥, and Cre mice were carrying the Cre recombinase under the control of the musclespecific muscle creatine kinase promoter (9, 25) . PPAR␥, peroxisome proliferator-activated receptor-␥; aP2, adipose-specific fatty acid-binding protein; IR, insulin resistance; HFD, high-fat diet; FFA, free fatty acids; TG, triglycerides; RFP, red fluorescence protein gene; m, male; f, female. Times (wk, mo) refer to age. *Serum levels in fasted mice. In the absence of specific indications, data are for the adult phenotype on a chow diet.
Mice deficient for PPAR␥ in skeletal muscle had significant whole body insulin resistance demonstrated either by insulin/ glucose tolerance tests or by hyperinsulinemic euglycemic clamp studies (9, 25) . However, the etiology of impaired insulin action in these mice remains to be defined. Hevener et al. (9) postulated that loss of PPAR␥ resulted in skeletal muscle insulin resistance followed by impaired insulin action in adipose tissue and liver. In contrast, Norris et al. (25) did not observe a change in muscular glucose disposal, whereas hepatic insulin sensitivity was impaired. Finally, the authors of both studies investigated the effects of TZDs in their model. TZD treatment did markedly improve systemic parameters of insulin sensitization independently of muscular PPAR␥ deficiency, once again underscoring the importance for adipose tissue and liver for TZD actions (9, 25) .
WHAT HAVE WE LEARNED FROM PPAR␥ DEFICIENCY IN FAT AND SKELETAL MUSCLE?
In contrast to the studies in adipose-specific PPAR␥-deficient mice, the data in muscle-specific PPAR␥ Ϫ/Ϫ mice demonstrate that whole body insulin sensitivity is, at least in part, dependent on an intact PPAR␥ system in skeletal muscle (Table 1 ). Despite the fact that PPAR␥ expression in muscle is only 5-10% of its expression in adipose tissue, PPAR␥ seems to play a central in role in maintaining regular insulin-mediated signaling in muscle, resulting in normal glucose disposal (1, 18, 36) . In addition, the studies by Hevener et al. (9) and Norris et al. (25) demonstrated that PPAR␥ deficiency in muscle results in secondary insulin resistance in adipose tissue and liver. These data suggest the existence of an important endocrine cross talk among muscle, fat, and liver, whose communicating molecules remain to be identified.
With respect to the pharmacological treatment of insulin resistance and type 2 diabetes mellitus, all studies in tissuespecific PPAR␥ knockout mice, except the study by Zhang et al. (38) , in which only PPAR␥2 was knocked out, have demonstrated that adipose tissue is the major primary target of TZD-induced insulin sensitization (8, 9, 14, 25) .
In conclusion, recent studies in tissue-specific PPAR␥ knockout mice have greatly increased our understanding of the role of different metabolic tissues in PPAR␥-mediated regulation of systemic insulin-stimulated glucose metabolism. The importance of adipose PPAR␥ to maintain systemic insulin sensitivity has convincingly been demonstrated. PPAR␥-mediated adipogenesis plays an important role in the protection against nonadipose tissue insulin resistance. Surprisingly, a small amount of muscular PPAR␥ contributes to intact systemic insulin sensitivity by maintaining intact insulin-mediated glucose utilization in muscle. Future studies are required to characterize the molecular network involved in the endocrine cross talk among fat, muscle, and liver. 
